A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help with weight.
What this means for you
- Who can join
- Adults 18+, have obesity, BMI 30+.
- What you take
- cagrilintide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The study runs about 18 months.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Obesity. Also studied in: Overweight.
Full scientific study title: Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events.
Who can join
Adults 18+, have obesity, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Male or female (sex at birth)
- Age 18 years or above at the time of signing the informed consent
- History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
- Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
- Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m^2)
Key exclusion criteria
- Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods
- Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
- History of type 1 or type 2 diabetes
- Glycated haemoglobin (HbA1c) >= 6.5 percent (%) (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening
- Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening
Where this study is enrolling
This trial has 11 sites across 6 states. Contact a site coordinator directly to start screening.
California1 site
- Diablo Clinical Research, Inc.Walnut Creek, California
Florida4 sites
- Northeast Research InstituteFleming Island, Florida
- Jacksonville Ctr For Clin ResJacksonville, Florida
- Center for Diab,Obes & MetabPembroke Pines, Florida
- Encore Medical Research of WestonWeston, Florida
North Carolina2 sites
- Monroe Biomedical Research, LLCMonroe, North Carolina
- AccellacareWilmington, North Carolina
South Carolina1 site
- Coastal Carolina Research CtrNorth Charleston, South Carolina
Tennessee1 site
- Holston Medical Group_BristolBristol, Tennessee
Texas2 sites
- Amarillo Medical SpecialistsAmarillo, Texas
- Elligo Clin Res CentreAustin, Texas
Timeline
Started enrolling: 2026-05-29. Expected completion: 2027-11-19. Last updated on ClinicalTrials.gov: 2026-05-26.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
